Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Verrica Pharmaceuticals, Inc.

Latest From Verrica Pharmaceuticals, Inc.

Verrica’s Anticancer Efforts Kick Off With Promising Early Phase II BCC Data

The US firm’s oncolytic peptide candidate, VP-315, has shown tumor clearance in a Phase II basal cell carcinoma trial, marking a positive start for its plans to expand from non-malignant dermatology to skin cancer.

Clinical Trials Cancer

Finance Watch: UroGen Accesses Cash After Phase III Bladder Cancer Success

Public Company Edition: UroGen raised $120m in a private placement of ordinary shares. Also, Verrica entered into a debt financing for up to $125m upon approval of Ycanth for molluscum contagiosum and job cuts were announced by Homology, Mersana, Infinity and others.

Financing Restructuring

Supplemental Filings: Ycanth Approved For Molluscum; CDER Counter-Terrorism Head Retires; 5 Benzodiazepines Added To Schedule I

The fourth review cycle is the charm for Verrica's cantharidin topical solution; Rosemary Roberts, head of CDER's Counter-Terrorism and Emergency Coordination Staff, retires after 35 years at the FDA; DEA deems five designer benzodiazepines with no currently accepted medical use in the US as Schedule I controlled substances.

Approvals FDA

Verrica Finally Gets Molluscum Treatment To The Finish Line

Verrica’s Ycanth, a drug-device combination product containing a formulation of cantharidin, is approved by the FDA as the first treatment for molluscum, after three complete response letters.

Approvals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals